GPIIbIIIa inhibitors as adjunctive therapy in acute myocardial infarction
| Autor: | Mahomed Y. Salame, Spencer B. King, Ranjit More, Stefan Verheye, Nicolas A.F. Chronos |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
medicine.medical_specialty
Platelet Aggregation Platelet aggregation medicine.medical_treatment Myocardial Infarction Primary angioplasty Platelet Glycoprotein GPIIb-IIIa Complex Internal medicine Angioplasty medicine Humans Thrombolytic Therapy cardiovascular diseases Myocardial infarction Angioplasty Balloon Coronary Randomized Controlled Trials as Topic Chemotherapy Aspirin business.industry Thrombolysis medicine.disease Treatment Outcome Concomitant Cardiology Drug Therapy Combination Cardiology and Cardiovascular Medicine business Platelet Aggregation Inhibitors medicine.drug |
| Zdroj: | International Journal of Cardiology. 69:231-236 |
| ISSN: | 0167-5273 |
| DOI: | 10.1016/s0167-5273(99)00046-7 |
| Popis: | Thrombolytic therapy has proved useful in the treatment of acute myocardial infarction but is frequently associated with limited vessel reperfusion and early reocclusion. Local platelet aggregation and activation play a role in these pathological processes, explaining the benefit of aspirin, a weak antiplatelet agent. Recent interest has turned to GPIIbIIIa antagonists, a class of potent inhibitors of platelet aggregation. Their concomitant use with fibrinolytics, in rescue and primary angioplasty for acute myocardial infarction treatment is explored. Efficacy and safety issues are addressed and the potential pivotal role of these agents in the treatment of acute myocardial infarction is discussed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect